Prognostic and clinicopathological significance of LOXL2 in cancers: A systematic review and meta‐analysis

Background Lysyl oxidase‐like 2 (LOXL2) is an extracellular matrix (ECM)‐modifying enzyme which can regulate the tensile strength of connective tissues by crosslink of collagen and elastin. Numerous studies have claimed correlations between LOXL2 expression and prognosis or clinicopathological chara...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cellular physiology 2019-11, Vol.234 (11), p.21369-21379
Main Authors: Zhang, Xuerui, Huang, Junfu, You, Fan, Li, Wang, Zou, Zhenhong
Format: Article
Language:English
Subjects:
Biomarkers
cancer
Collagen (type I)
Connective tissues
Correlation analysis
Cross-linking
Crosslinking
Elastin
Extracellular matrix
LOXL2
Lymph nodes
Lysyl oxidase
Medical prognosis
Meta-analysis
Metastases
Parameters
Prognosis
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Lysyl oxidase‐like 2 (LOXL2) is an extracellular matrix (ECM)‐modifying enzyme which can regulate the tensile strength of connective tissues by crosslink of collagen and elastin. Numerous studies have claimed correlations between LOXL2 expression and prognosis or clinicopathological characteristics in various cancers. However, the validities of these claims are still in question. To address these experimental results, a meta‐analysis was done to assess the prognostic and clinicopathological significance of LOXL2 expression in various cancers. Methods The keywords were used for searching systematically in PubMed, Web of Science, Embase, Wanfang database, and CNKI. Stata SE15.0 was used for meta‐analysis. The hazard ratio (HR) and odds ratios (ORs) were pooled to assess the relationship between LOXL2 expression and overall survival (OS), disease‐free survival (DFS), and clinicopathological parameters. Results Seventeen studies with 3,881 patients were considered as valid studies. The results indicated that the patients who had a positive LOXL2 expression had a shorter OS (HR 1.60, 95% CI 1.26–1.94, p 
ISSN:0021-9541
1097-4652
DOI:10.1002/jcp.28746